前列腺癌患者同源修复缺乏测试的治疗意义（第2部分，共2部分）
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)
影响因子:5.80000
发表日期:2024 Sep 27
作者:
Anthony V Serritella, Amy Taylor, Michael C Haffner, Wassim Abida, Alan Bryce, Lawrence I Karsh, Scott T Tagawa, Przemyslaw Twardowski, Andrew J Armstrong, Joshua M Lang
摘要
不幸的是，并非所有抗性cast割的前列腺癌（MCRPC）患者都可以接受可用的寿命全身疗法，从而强调需要优化MCRPC治疗选择。确定前列腺癌的基因测试是必要的。在这本两部分的基于专家意见的指南中，我们就使用种系的利用和躯体测试来检测MCRPC患者的HRR改变提供了专家共识。本指南是由一个多学科专家小组开发的，该小组于2023 - 2024年召集，包括医学肿瘤学，泌尿外科，放射肿瘤学，病理学，病理学，医学基因组学和基础科学的代表。在第二部分中，我们重点介绍了基因测试如何基于MCRPC批准的批准和近期阶段的批准，并如何导致遗传测试，并如何实现。 MCRPC中的抑制剂。
Abstract
Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer.In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science.In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.